Live in the OR Interview

Anteris CEO Wayne Paterson

Interview with the implanting physicians from the DurAVR First-in-Human Study

POWERED BY SCIENCE. DEVELOPED BY EXPERTS.

Engineered to deliver the most durable heart valve for patients with severe aortic stenosis - DurAVR™ Transcatheter Heart Valve elevates science and enhances the human life.

Learn More

INSPIRED BY HUMANS
EMPOWERED BY PURPOSE.

Anteris Technologies is a Structural Heart Company committed to discovering, developing, and delivering a pipeline of innovative medical device solutions that aim to improve the health outcomes of patient populations and dramatically improve people's lives.

INVESTOR CENTER

We drive awareness and adoption of our ADAPT technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.

Learn More

LATEST ANTERIS NEWS

Breaking News
DurAVR™ THV EFS

US FDA grants DurAVR™ THV
approval for Early Feasibility Study (EFS)

November 2022

ASX Announcement

PCR London Valves: Expert Interview

DurAVR THV Impact of Novel Leaflet Design on Hemodynamics and Physiology

Presented by:

Faculty: Bernard Prendergast, MD
Joao Cavalcante, MD, and Chris Meduri, MD

Watch Here

PCR London Valves: Late Breaking Clinical Trial

DurAVR THV First-in-Human Study, 30-day Results
Presented by Chris Meduri, MD
Karolinska University Medical Center, Sweden

View Here

PCR London Valves: Rapid Fire Abstract

DurAVR THV Novel Leaflet Design Restores Aortic Flow and Hemodynamics on Cardiac MRI Analysis
Presented by Pankaj Garg, MD
University of East Anglia, United Kingdom